NewAmsterdam Pharma

04/16/2026

Congratulations to our CEO, Dr. Michael Davidson who has been selected for the 2026 Foundation of the NLA Clinician/Educator Award.

From patient care to education, his work continues to elevate the field of clinical lipidology, and we’re proud to see it recognized on this stage.

See you at as we celebrate with National Lipid Association and Foundation of the National Lipid Association.

04/07/2026

On , we’re recognizing the importance of prevention, early detection, and access to care, particularly for cardiovascular disease, the leading cause of death worldwide.

We’re committed to advancing science that can help address unmet needs in cardiovascular disease and other lipid-related conditions and keeping patients at the heart of our work. Learn more about our focus: https://www.newamsterdampharma.com/

04/01/2026

We’re proud to see our Chief Scientific Officer, Prof. John Kastelein, honored by the Family Heart Foundation with the Pioneer Award.

Prof. Kastelein’s groundbreaking work has played a pivotal role in advancing how cardiovascular disease is understood and treated the understanding and treatment of cardiovascular disease around the world. This recognition reflects decades of scientific leadership and innovation that continue to drive progress for patients.

Congratulations, Prof. Kastelein, on this well-deserved honor. We’re grateful for your commitment to advancing scientific research and treatment options.

The Family Heart Foundation is proud to honor Dr. John Kastelein, University of Amsterdam, with the Pioneer Award at our 2026 Global Summit — Small Steps and Giant Leaps: Charting a Course for Cardiovascular Disease Prevention. Dr. Kastelein’s groundbreaking work in lipid science and cardiovascular prevention has helped shape how we understand and treat inherited cholesterol conditions. We are excited to announce him as the Pioneer Award winner and as a keynote speaker! Join us as we recognize his impact and hear his insights from decades of innovation. Register today for early bird pricing at https://FamilyHeart.org/Summit

03/31/2026

We are working to change the landscape of lipid-lowering treatment by advancing innovative therapies for cardiovascular disease (CVD) and other lipid-related conditions. As we continue to advance our Phase 3 clinical program, we will be hiring many roles and encourage you to follow us to learn more about our current openings and stay updated on future job postings: https://www.newamsterdampharma.com/careers/

03/26/2026

Diabetes and cardiovascular disease often intersect. Today, on , it’s important to understand lipid-related conditions and their role in long-term cardiovascular health. Learn more about lipid-related conditions and our focus: https://www.newamsterdampharma.com/lipid-related-conditions/

03/24/2026

Lipoprotein(a), or Lp(a), is an often under-recognized risk factor for cardiovascular disease. Since Lp(a) levels are largely genetically determined, lifestyle changes alone may not be enough to lower elevated risk, and many people are unaware of their levels without testing.

On , learn more about the role of Lp(a) in cardiovascular risk: https://www.expectmoreforldl.com/ldl-c-and-beyond/

03/18/2026

Cholesterol plays a critical role in brain function, and scientists are increasingly studying how disruptions in cholesterol metabolism may contribute to Alzheimer’s disease. This research is especially relevant for people who carry the APOE4 gene, who face a substantially higher risk of developing the disease.

In a Nature article, we explain how cholesterol metabolism and cardiometabolic risk may be connected to brain health and highlight new tests that could help identify risk earlier and support prevention. Read more: https://link.springer.com/article/10.1007/d43592-026-00008-z

03/16/2026

Heart health and brain health are closely connected. During , we’re highlighting emerging research into how cholesterol and lipid metabolism, which are well established in cardiovascular disease, may also play a role in Alzheimer’s disease.

Learn more about cholesterol’s role in brain function: https://www.newamsterdampharma.com/lipid-related-conditions/

03/06/2026

On , we’re grateful for the 105 team members across five countries and 19 states whose dedication, insight, and heart drive our work. Together, they bring purpose to our progress in advancing science for cardiovascular disease and other lipid-related conditions.

02/16/2026

Alzheimer’s and Dementia Care Education Week is a timely reminder that understanding and managing lipids may support long-term brain health and overall well-being.

Learn more about the connection between lipids and Alzheimer’s disease: https://www.newamsterdampharma.com/lipid-related-conditions/?utm_source=fb&utm_medium=organic&utm_campaign=alzheimer’s-&dementia-care-education-week&utm_content=lipid-related-conditions

02/06/2026

On Wear Red Day, we’re shining a light on a risk that often hides in plain sight: as estrogen declines during menopause, cardiovascular risk rises.

Lifestyle changes, regular check-ins, and, when appropriate, medical intervention can help women protect their long-term heart health.

Learn more about risk factors associated with cardiovascular disease. https://www.newamsterdampharma.com/our-focus/

02/03/2026

Atherosclerosis develops quietly, long before symptoms appear. For many, it’s not just lifestyle—it’s genetics, inherited risk, and the way their blood vessels respond to the world around them.

Listen as Prof. Kausik Ray explains why caring for your blood vessels today can prevent urgent problems tomorrow.

Learn more about cardiovascular risk factors: https://bit.ly/45K5fLY